Psychedelic Stocks Surge After Trump Executive Order
Psychedelic-related stocks jumped sharply in premarket trading on Monday after U.S. President Donald Trump signed an executive order aimed at accelerating research and expanding patient access to psychedelic treatments. These therapies have shown strong potential in addressing post-traumatic stress disorder (PTSD) and other serious mental health conditions.
Major Psychedelic Stocks Lead the Rally
Several companies in the sector posted significant gains following the announcement. Compass Pathways surged more than 25% in premarket trading, while Atai Beckley, Definium Therapeutics, and GH Research recorded gains ranging between 14% and 18%.
Government Support Boosts Sector Confidence
During the signing ceremony at the Oval Office, Trump emphasized the transformative potential of these treatments, particularly for individuals suffering from severe mental illnesses and veterans dealing with PTSD.
The administration also revealed a $50 million federal investment to support further research into ibogaine, a psychedelic compound derived from an African plant that is being studied for its potential to treat opioid addiction and trauma-related disorders.
Analysts See Strong Upside Potential
Market analysts believe the executive order represents a major turning point for the psychedelic sector. According to Jefferies analyst Andrew Tsai, the move signals strong institutional support from key agencies, including the FDA, HHS, and the White House.
With multiple government bodies aligned, investor interest in psychedelic stocks is expected to grow significantly ahead of potential regulatory approvals between 2027 and 2030.
Faster Approval Process Could Accelerate Growth
The executive order directs the FDA to grant priority review vouchers to psychedelic therapies that have already received breakthrough therapy designations. This could dramatically shorten the typical drug review timeline from six to ten months down to as little as one to two months.
Analysts highlighted several companies that could benefit from these developments, including Atai Beckley, Definium Therapeutics, Helus Pharma, Compass Pathways, Otsuka, and Reunion Neuroscience.
Regulatory Changes Aim to Expand Access
In addition to speeding up approvals, the FDA and DEA have been instructed to establish clearer pathways for patient access. The order also calls for the reassessment of psychedelics’ classification, which are currently listed as Schedule I controlled substances.
These regulatory changes could play a crucial role in bringing psychedelic therapies to market faster and expanding treatment options for patients worldwide.
